Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8999672rdf:typepubmed:Citationlld:pubmed
pubmed-article:8999672lifeskim:mentionsumls-concept:C0019163lld:lifeskim
pubmed-article:8999672lifeskim:mentionsumls-concept:C0337816lld:lifeskim
pubmed-article:8999672lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:8999672lifeskim:mentionsumls-concept:C0042210lld:lifeskim
pubmed-article:8999672lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:8999672lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:8999672pubmed:issue4lld:pubmed
pubmed-article:8999672pubmed:dateCreated1997-1-23lld:pubmed
pubmed-article:8999672pubmed:abstractTextTwo yeast recombinant vaccines were compared: the Russian hepatitis B Combiotech vaccine in a dose of 20 mg and the Recombivax-HB vaccine in a dose of 10 mg manufactured in the USA (Merk, Sharp and Dohme Ltd.). Both agents were found safe and low reactogenic. After a course of 3 vaccinations with the Russian vaccine 92.5 to 97.5% subjects vaccinated after the 0-1-2 months and 0-1-6 months protocols had high levels of specific antibodies. In the group vaccinated with the American vaccine, antibodies to HBsAg were found in the sera of 95 to 100% subjects. These results demonstrate high immunological activity of both Russian and American vaccines.lld:pubmed
pubmed-article:8999672pubmed:languageruslld:pubmed
pubmed-article:8999672pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8999672pubmed:citationSubsetIMlld:pubmed
pubmed-article:8999672pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8999672pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8999672pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8999672pubmed:statusMEDLINElld:pubmed
pubmed-article:8999672pubmed:issn0507-4088lld:pubmed
pubmed-article:8999672pubmed:authorpubmed-author:BorisovaV NVNlld:pubmed
pubmed-article:8999672pubmed:authorpubmed-author:PavlovaL ILIlld:pubmed
pubmed-article:8999672pubmed:authorpubmed-author:IakovlevaI...lld:pubmed
pubmed-article:8999672pubmed:authorpubmed-author:GorbunovM AMAlld:pubmed
pubmed-article:8999672pubmed:authorpubmed-author:Krasil'nikovI...lld:pubmed
pubmed-article:8999672pubmed:authorpubmed-author:SkvortsovS...lld:pubmed
pubmed-article:8999672pubmed:authorpubmed-author:Lytsar'B NBNlld:pubmed
pubmed-article:8999672pubmed:authorpubmed-author:NoskovaA VAVlld:pubmed
pubmed-article:8999672pubmed:authorpubmed-author:TitovI AIAlld:pubmed
pubmed-article:8999672pubmed:authorpubmed-author:BeliakovaE...lld:pubmed
pubmed-article:8999672pubmed:authorpubmed-author:BudanovM VMVlld:pubmed
pubmed-article:8999672pubmed:authorpubmed-author:Bel'chenkoA...lld:pubmed
pubmed-article:8999672pubmed:authorpubmed-author:KorovinIu...lld:pubmed
pubmed-article:8999672pubmed:issnTypePrintlld:pubmed
pubmed-article:8999672pubmed:volume41lld:pubmed
pubmed-article:8999672pubmed:ownerNLMlld:pubmed
pubmed-article:8999672pubmed:authorsCompleteYlld:pubmed
pubmed-article:8999672pubmed:pagination170-2lld:pubmed
pubmed-article:8999672pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8999672pubmed:meshHeadingpubmed-meshheading:8999672-...lld:pubmed
pubmed-article:8999672pubmed:meshHeadingpubmed-meshheading:8999672-...lld:pubmed
pubmed-article:8999672pubmed:meshHeadingpubmed-meshheading:8999672-...lld:pubmed
pubmed-article:8999672pubmed:meshHeadingpubmed-meshheading:8999672-...lld:pubmed
pubmed-article:8999672pubmed:meshHeadingpubmed-meshheading:8999672-...lld:pubmed
pubmed-article:8999672pubmed:meshHeadingpubmed-meshheading:8999672-...lld:pubmed
pubmed-article:8999672pubmed:articleTitle[Russian recombinant vaccine against hepatitis B (results of controlled trials)].lld:pubmed
pubmed-article:8999672pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8999672pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8999672pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:8999672pubmed:publicationTypeRandomized Controlled Triallld:pubmed